Accessibility Menu
Zivo Bioscience logo

Zivo Bioscience(OTC) ZIVO

Market Cap$19.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-76%
1 Year-55%
1 Month+11%
$5.00
+25%
+1.00Today
Zivo Bioscience last closing stock price
MetricPriceDate
Last closeUSD 5.002026-07-27
Zivo Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+22.55%USD 4.082026-07-20
1 month+11.11%USD 4.502026-06-26
3 month+141.55%USD 2.072026-04-28
Year to date-42.53%USD 8.702025-12-31
1 year-54.75%USD 11.052025-07-25
3 year-57.48%USD 11.762023-07-28
5 year-76.46%USD 21.242021-07-28
Since inception-99.68%USD 1,560.002003-10-30

Zivo Bioscience Financials at a Glance

Market Cap

$19.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$119.03K

Net Income (TTM)

-$6.63M

EPS (TTM)

-$1.71

P/E Ratio

-2.92

Dividend

$0.00

Beta (Volatility)

0.31 (Low)

Price

$5.00

Volume

1

Open

$4.00

Previous Close

$5.00

Daily Range

$3.99 - $5.00

52-Week Range

$1.11 - $19.65

Estimated Earnings Date

Sep 2, 2026

ZIVO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zivo Bioscience

ZIVO creates natural ingredients from algae for food and health products. Its solutions help animal and human health industries improve nutrition and wellness.

What’s on the Menu? ZIVO’s Core Offerings

  • Algal Biomass (100% of revenue for the six months ended June 30, 2025): Dried algae powder for use in human foods and supplements.
  • Bioactive Compounds: Algae-derived ingredients for animal health, such as poultry gut support and bovine mastitis management.
  • Functional Food Ingredients: Algal products for nutritional enhancement in packaged foods and beverages.
  • Skin Health Applications: Algae-based ingredients for topical and ingestible skin health products.
  • Immune Modulation: Algal compounds aimed at supporting human immune function.

Growth and Expansion: ZIVO’s Moves on the Board

  • Launched commercial sales of algal biomass for human food in 2025.
  • Engaged ZWorldwide as independent distributor for North American market entry in 2025.
  • Opened new lab and office leases in Michigan and Florida in early 2025.
  • Converted investor revenue share rights to equity in 2025, reducing future cash obligations.

What Makes ZIVO Stand Out?

ZIVO’s proprietary algae strains and production methods set it apart in the biotech sector. The company targets non-antibiotic solutions for animal health, addressing markets with limited innovation. Its self-affirmed GRAS status allows use in both human and animal food products.

Five Things You Need to Know

  • Revenue was $53,400 in Q2 2025, up 1,218.5% from Q2 2023.
  • Net loss was $2 million in Q2 2025, improving 80.1% from Q2 2024.
  • Cash was $9,823 as of June 30, 2025, down from $1.5 million at year-end 2024.
  • All revenue in 2025 came from algal biomass sales for human food use.
  • Company reported an accumulated deficit of $142.8 million as of June 30, 2025.

Bottom Line

ZIVO has shifted from research to commercial sales of algae-based ingredients. The company faces ongoing financial challenges but continues to develop new applications for its proprietary technology.

AI Generated • Apr 16, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

7

CEO

John Bernard Payne, MBA

Website

www.zivobioscience.com

Headquarters

Troy, MI 48304, US

ZIVO Financials

Key Financial Metrics (TTM)

Gross Margin

32.94%

Operating Margin

-5535.47%

Net Income Margin

-5572.45%

Return on Equity

204.08%

Return on Capital

N/A

Return on Assets

-1283.44%

Earnings Yield

-34.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.89M

Volume

1

Avg. Volume

1.68K

Financials (TTM)

Gross Profit

$39.21K

Operating Income

-$6.59M

EBITDA

-$6.59M

Operating Cash Flow

-$2.07M

Capital Expenditure

-$1.00

Free Cash Flow

-$2.07M

Cash & ST Invst.

$4.02K

Total Debt

$772.03K

Zivo Bioscience Performance Analysis

Zivo Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 27,650N/A
20242024-12-31USD 157,220468.6%
20252025-12-31USD 119,025-24.3%
Zivo Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3022.9%
Q42025-12-31-100.0%
Q12026-03-31N/A
Zivo Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5.57-19.1%
20232023-12-31USD -4.60-17.4%
20242024-12-31USD -4.23-8.2%
20252025-12-31USD -2.59-38.7%
Zivo Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3061.6%
Q32025-09-3037.2%
Q42025-12-31-185.2%
Q12026-03-3168.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$19.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.78M

N/A

Employees

7

N/A

Net Income

-$951.49K

+77.4%

EBITDA

-$942.76K

+77.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.02K

-99.2%

Total Debt

$772.03K

-13.6%

Accounts Receivable

$0.00

N/A

Inventory

$259.79K

N/A

Long Term Debt

$183.53K

-63.9%

Short Term Debt

$588.49K

-15.9%

Return on Assets

-12.83%

N/A

Return on Invested Capital

2.03%

N/A

Free Cash Flow

-$210.70K

+85.3%

Operating Cash Flow

-$210.70K

+85.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTLCOncotelic Therapeutics, Inc.
$0.04+14.29%
RLFTFMindMaze Therapeutics Holding S.A.
$0.22+12.00%
PSYBFPsyBio Therapeutics Corp
$0.00+0.00%
ACHFFArch Biopartners Inc.
$0.58+4.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About ZIVO

What is the current price of Zivo Bioscience?

Zivo Bioscience is trading at $5.00 per share.

What is the 52-week range for Zivo Bioscience?

Over the past 52 weeks, Zivo Bioscience has traded between $1.11 and $19.65.

How much debt does Zivo Bioscience have?

As of the most recent reporting period, Zivo Bioscience reported total debt of $772.03K.

How much cash does Zivo Bioscience have on hand?

Zivo Bioscience reported $4.02K in cash and cash equivalents in its most recent financial results.

What is Zivo Bioscience’s dividend yield?

Zivo Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services